NV-SPHERICAM
Sphericam 2, the world’s first 360˚ VR camera capable of self-stitching and livestreaming 4K video in real-time will start shipping this summer. Full-scale production is scheduled to begin at a U.S. production facility this July following a successful Kickstarter campaign and new $5 million investment from China’s Kingnet Technologies.
“The Sphericam 2 is like no other camera on the market. With a global shutter capable of shooting at 60 frames per second and the ability to self-stitch and livestream 4K video, it sets a new bar for performance. It’s also incredibly compact, roughly the size of a baseball. We designed the camera with professionals in mind which is why we’re thrilled use our presence at NAB to announce it will be available this summer” says Jeffrey Martin, Sphericam founder and CEO. The National Association of Broadcasters trade show in Las Vegas marks the first time the public will be able to view a live demo of the Sphericam 2.
The camera was first announced on Kickstarter in 2015 where it received backing of $450,000, more than four times the initial target.
“Our Kickstarter backers and pre-order customers will be the first to receive the Sphericam 2 once it ships. We also have large media and technology companies eager to start using the camera. The recent investment from Kingnet helps us not only accelerate our production timetable but to broaden our product and service portfolio,” says Martin.
The Shanghai-based online and mobile gaming company Kingnet is investing $5 million as part of a new strategic focus on VR content.
“We invested in Sphericam because it’s clear that it’s more than just a VR hardware company,” Wang Yue, CEO of Kingnet Technologies. “Sphericam is building a bridge between people’s real-world experiences and the VR space. The Sphericam 2 allows people to capture and share 360˚ video in a format that’s perfect for today’s virtual reality headsets and this is only the beginning.
Sphericam will be important part of Kingnet’s “platform+content+VR” strategy far into the future.”
The Sphericam 2 is available for pre-order at a cost of $2500.
Visit us at NAB 2016, Las Vegas, USA
April 16th – 21st
Booth N8022
North Hall, VR Pavilion
About Sphericam
Founded by American photographer Jeffrey Martin along with Dutch hardware specialist Servaes Joordens and software specialist Poppo Wit in 2014, Sphericam is dedicated to building groundbreaking 360˚ cameras to create original content for virtual reality platforms and interactive online media. The company’s newest product, called Sphericam 2, is an immersive capture device capable of self-stitching and streaming live 4K video at 60 frames per second. The company has offices in Prague, Haarlem, Haaren and Ljubljana.
Images and example 360˚ video content: http://bit.do/sphericam
View source version on businesswire.com: http://www.businesswire.com/news/home/20160417005021/en/
Contact:
Media contact
US:
Gaja Zornada
gaja@sphericam.com
+38-64-1215-430
+1-401-3-430-430
or
George
Krieger
press@sphericam.com
+1-831-717-7214
or
Europe:
Marc
Rettig
marc.Rettig@nelsonbostockunlimited.com
T
+44-7814-794253
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpega Group Completes Leadership Succession Plan Appointing Daniel Cohen New CEO8.1.2026 10:03:00 CET | Press release
Alpega Group, a leading pan-European provider of an end-to-end transportation and logistics platform, today announced a planned leadership transition. After a successful tenure as Chief Executive Officer, Todd DeLaughter will be retiring, stepping down from his role and transitioning to a Board Advisor role for the company. The Board of Directors has appointed Daniel Cohen as the incoming CEO, effective January 1st, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108528648/en/ Daniel Cohen, CEO Alpega Daniel Cohen brings three decades of experience leading B2B SaaS businesses through periods of change, scale, and value realization. Most recently, as CEO of PayU, he led a full financial, operational, and cultural transformation returning the business to sustained profitable growth. He subsequently steered the company through a highly complex, multi-jurisdictional process that culminated in the successful sale to Rapyd
FPT Named Sitecore’s First Global Partner Under Global Elite Reseller Program8.1.2026 09:00:00 CET | Press release
Global IT Corporation FPT announced its appointment as the inaugural Global Elite Reseller under a new initiative from Sitecore that expands upon its successful Global Reseller Program. The Global Elite Reseller Program follows the launch of SitecoreAI, the next-generation digital experience platform that puts artificial intelligence at the center of marketing, unifying content, data, and personalization in one composable platform so organizations can reach, engage, and serve their audience across digital channels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107425261/en/ Representatives from FPT and Sitecore at the Global Elite Reseller signing ceremony. Under the agreement, FPT will hold exclusive reseller rights in Vietnam and non-exclusive rights across select markets in Asia and the Middle East, taking SitecoreAI to market and showing how it helps teams plan, create, and optimize digital experiences using AI as cu
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom